Tags

Type your tag names separated by a space and hit enter

Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
East Afr Med J 1999; 76(6):307-13EA

Abstract

OBJECTIVE

To investigate if there is a difference in response to tuberculosis treatment between HIV seronegative and HIV seropositive patients following two months of intensive phase tuberculosis treatment.

DESIGN

Prospective cohort study.

SETTING

St. Francis Leprosy Centre, south-east Uganda.

SUBJECTS

Four hundred fifty seven patients with never previously treated sputum smear-positive tuberculosis admitted during a two-year period in 1991/1993.

INTERVENTION

Intensive phase treatment with streptomycin, isoniazid, rifampicin and pyrazinamide.

MAIN OUTCOME MEASURES

Sputum conversion from a positive to a negative smear at eight weeks of treatment.

RESULTS

HIV seropositivity prevalence was 28%. Among HIV seronegative patients, conversion to a negative smear status occurred in 76% persons compared to 78% in HIV seropositive patients. This difference was not statistically significant (OR = 0.9; 95% CI, 0.6-1.5). HIV seropositive patients, however, were more likely to die (p = 0.017). A high prevalence of resistance to isoniazid and streptomycin was found. Isoniazid resistance was more likely in HIV seronegative patients with M. tuberculosis strains compared to HIV seropositive persons (p < 0.005). Initial resistance to antituberculosis drugs did not have a significant effect on smear conversion.

CONCLUSION

This study demonstrates that HIV-seropositive status is not a principal factor in delaying sputum conversion among patients receiving intensive phase tuberculosis treatment.

Authors+Show Affiliations

St. Francis Leprosy Centre, Buluba, Uganda.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

10750516

Citation

Bwire, R, et al. "Tuberculosis Chemotherapy and Sputum Conversion Among HIV-seropositive and HIV-seronegative Patients in South-eastern Uganda." East African Medical Journal, vol. 76, no. 6, 1999, pp. 307-13.
Bwire R, Borgdorff MW, Sticht-Groh V, et al. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. East Afr Med J. 1999;76(6):307-13.
Bwire, R., Borgdorff, M. W., Sticht-Groh, V., Rieder, H. L., Kawuma, H. J., Bretzel, G., & Rüsch-Gerdes, S. (1999). Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. East African Medical Journal, 76(6), pp. 307-13.
Bwire R, et al. Tuberculosis Chemotherapy and Sputum Conversion Among HIV-seropositive and HIV-seronegative Patients in South-eastern Uganda. East Afr Med J. 1999;76(6):307-13. PubMed PMID: 10750516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. AU - Bwire,R, AU - Borgdorff,M W, AU - Sticht-Groh,V, AU - Rieder,H L, AU - Kawuma,H J, AU - Bretzel,G, AU - Rüsch-Gerdes,S, PY - 2000/4/6/pubmed PY - 2000/4/25/medline PY - 2000/4/6/entrez KW - Africa KW - Africa South Of The Sahara KW - Antibiotics--therapeutic use KW - Developing Countries KW - Diseases KW - Drugs KW - Eastern Africa KW - English Speaking Africa KW - Hiv Infections KW - Infections KW - Prospective Studies KW - Research Methodology KW - Research Report KW - Studies KW - Treatment KW - Tuberculosis KW - Uganda KW - Viral Diseases SP - 307 EP - 13 JF - East African medical journal JO - East Afr Med J VL - 76 IS - 6 N2 - OBJECTIVE: To investigate if there is a difference in response to tuberculosis treatment between HIV seronegative and HIV seropositive patients following two months of intensive phase tuberculosis treatment. DESIGN: Prospective cohort study. SETTING: St. Francis Leprosy Centre, south-east Uganda. SUBJECTS: Four hundred fifty seven patients with never previously treated sputum smear-positive tuberculosis admitted during a two-year period in 1991/1993. INTERVENTION: Intensive phase treatment with streptomycin, isoniazid, rifampicin and pyrazinamide. MAIN OUTCOME MEASURES: Sputum conversion from a positive to a negative smear at eight weeks of treatment. RESULTS: HIV seropositivity prevalence was 28%. Among HIV seronegative patients, conversion to a negative smear status occurred in 76% persons compared to 78% in HIV seropositive patients. This difference was not statistically significant (OR = 0.9; 95% CI, 0.6-1.5). HIV seropositive patients, however, were more likely to die (p = 0.017). A high prevalence of resistance to isoniazid and streptomycin was found. Isoniazid resistance was more likely in HIV seronegative patients with M. tuberculosis strains compared to HIV seropositive persons (p < 0.005). Initial resistance to antituberculosis drugs did not have a significant effect on smear conversion. CONCLUSION: This study demonstrates that HIV-seropositive status is not a principal factor in delaying sputum conversion among patients receiving intensive phase tuberculosis treatment. SN - 0012-835X UR - https://www.unboundmedicine.com/medline/citation/10750516/Tuberculosis_chemotherapy_and_sputum_conversion_among_HIV_seropositive_and_HIV_seronegative_patients_in_south_eastern_Uganda_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -